A Brief Update on the Management of Hepatitis Delta
- 42 Downloads
Hepatitis delta (HDV) is an incomplete virus requiring hepatitis B (HBV), specifically hepatitis B surface antigen (HBsAg) to replicate. HDV can present as an acute or chronic infection and has been described as the most severe chronic viral hepatitis . HDV has a seroprevalence of approximately 5% of persons with chronic HBV with an estimated 15–20 million people infected with HDV worldwide [2, 3]. Fortunately, the number of HDV-infected persons has decreased since the 1990s due to the successful global HBV vaccination program . The only approved treatment agent for HDV is interferon (IFN)-α; however, pegylated interferon is the current standard of care. Interferon-based therapy is limited by poor response, high rates of relapse, and adverse effects [5, 6]. Presently, there are three novel therapies that are being evaluated for chronic HDV infection, lonafarnib , REP2139-CA , and myrcludex B [1, 9]. Given the severity of HDV, newer and more effective...
- 1.Chen H-Y, Shen D-T, Ji D-Z, Han P-C, Zhang W-M, Ma J-F, et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. Gut. 2018;18Google Scholar
- 3.“Hepatitis D” World Health Organization, World Health Organization, July 2018, www.who.int/news-room/fact-sheets/detail/hepatitis-d.
- 8.Bazinet M, Pântea V, Cebotarescu V, Cojuhari L, Jimbei P, Albrecht J, et al. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2017;2(12):877–89.CrossRefGoogle Scholar
- 17.Farci P, Anna NG. Current and future management of chronic hepatitis D. Gastroenterol Hepatol. 2018 Jun;14(6):342–51.Google Scholar
- 21.Wedemeyer H, Bogomolov P, Blank A, Allweiss L, Dandri-Petersen M, Bremer B, et al. Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of myrcludex B in combination with tenofovir in patients with chronic HBV/HDV co-infection. J Hepatol. 2018 Apr 1;68:S3.CrossRefGoogle Scholar
- 25.Wedemeyer H, Port K, Deterding K, Wranke A, Kirschner J, Bruno B, et al. A phase 2 dose-escalation study of lonafarnib plus ritonavir in patients with chronic hepatitis D: final results from the lonafarnib with ritonavir in HDV-4 (LOWR HDV-4) study. J Hepatol. 2017 Jan 1;66(1):S24.CrossRefGoogle Scholar